bmiMD Review: $99 a month, the same at every dose, and a clean regulatory record
bmiMD publishes the cheapest GLP-1 pricing we have been able to verify anywhere — $99/month for compounded semaglutide, with no separate membership fee and the provider visit included. Two things make that price more interesting than a headline number: it is the same at every dose, so it does not climb as you titrate, and bmiMD is one of the few programs here that publishes the actual potency and sterility specifications its pharmacies test against. It is also the only compounded-only program on this site with no FDA warning letter, no FTC action and no lawsuit on record.
- $99/month, and we verified it ourselves on bmiMD’s own site. Not an affiliate figure, not a teaser rate that evaporates — the published 12-month price for compounded semaglutide, with no membership fee stacked on top and the provider visit included. Nothing else in this roundup gets close.
- The same price at every dose. This quietly matters more than the headline. Dose-based escalation is how a $99 plan becomes a $300 plan by month four at other providers. Here your month-one number is your month-twelve number.
- It publishes what it tests for. Potency within ±10%, USP 797 sterility, pH, and USP 85 endotoxin testing. Most compounded programs say “quality-tested” and leave it there; bmiMD names the specifications, which is the kind of disclosure you can actually hold a company to.
- A clean regulatory record. We searched and found no FDA warning letter, no FTC action, no state attorney general action and no lawsuit naming bmiMD or MEDCCM. Three of the six programs in our roundup cannot say that.
- Financing built in, and honest labelling. Klarna, Afterpay, FSA and HSA are all accepted, and bmiMD states plainly on its own site that compounded medications are not FDA-approved — a disclosure the regulator has had to force out of other companies.
- Worth knowing before you prepay: the $99 rate requires $1,188 up front, the BBB grade is C+ with a low customer review average, bmiMD replies to only about one negative review in ten, and its terms and conditions page currently returns a 404. Read the two sections below before you commit twelve months.
Pricing — verified on bmiMD’s own site
Unlike the other two programs on this site, bmiMD’s pricing is actually legible. There is no membership fee stacked on top of the medication, the provider visit is included, and shipping is free. The price falls as you prepay for longer.
| Term | Compounded semaglutide | Compounded tirzepatide |
|---|---|---|
| 1 month | $129/mo | $179/mo |
| 3 months | $119/mo ($357 up front) | $159/mo ($477 up front) |
| 6 months | $109/mo ($654 up front) | $149/mo ($894 up front) |
| 12 months | $99/mo ($1,188 up front) | $139/mo ($1,668 up front) |
bmiMD states the price is the same at every dose, which removes the most common hidden-escalation problem in this category. FSA/HSA cards, Klarna and Afterpay are accepted — bmiMD is the only program on this site that puts buy-now-pay-later financing in front of you at checkout, which for a $1,188 twelve-month commitment is a meaningful piece of plumbing.
The quality specifications bmiMD actually publishes
This is the most underrated thing about bmiMD and the reason it outranks two better-known brands in our roundup. Almost every compounded GLP-1 program tells you its medication is “quality-tested” and stops there. bmiMD names the tests: potency within ±10% of label, USP <797> sterility, pH, and USP <85> bacterial endotoxin testing on the compounded product.
Those are the standard release specifications a sterile compounding pharmacy should be meeting, so bmiMD is not claiming anything exotic. The point is that it commits to them in writing, in public, where you can ask about them — and it pairs that with a plain statement on its own site that compounded medications are not FDA-approved. In a category where the FDA has spent a year sending letters about companies blurring exactly that line, a provider that volunteers the limitation is telling you something about how it operates.
Three pricing inconsistencies to be aware of
We check pricing consistency as a proxy for how carefully a company is run. bmiMD has three discrepancies live at once, and none of them changes the $99 figure we verified — but they are the reason we tell you to buy from bmiMD’s own product page rather than from anyone quoting it:
| What we saw | Why it matters |
|---|---|
| The homepage advertises tirzepatide “starting at $149” while the tirzepatide product page shows $139. | A $10/month contradiction between two pages of the same site. |
| A banner reading “New Year’s Sale is LIVE! Get 20% OFF” was running in late July. | Either the banner is stale by six months, or the sale is permanent and the name is decoration. Neither is a good sign for taking urgency claims at face value. |
| Affiliate partner pages quote $199/month against a “regular price” of $379/month. | Neither figure matches any price published on bmiMD’s own site. A $379 anchor that exists nowhere in the actual product catalogue is an anchor, not a price. |
The ratings: a friendly Trustpilot, a harsher BBB
bmiMD trades as MEDCCM, Inc., a New York corporation registered on 31 December 2022, at 420 Lexington Avenue, Room 1402, New York, NY 10170.
The Better Business Bureau rates it C+ and it is not accredited. There are 38 complaints on file, including at least one closed for failure to respond, and the BBB customer review average is 1.28 out of 5 from 25 reviews.
Trustpilot tells a friendlier story. The US listing blocks automated access, so we read the country mirrors: 3.7 from 617 reviews (AU), 3.6 from 607 (CA), 3.5 from 608 (NZ). Call it roughly 3.5 to 3.7 from about 600 reviews. As with TrimRx, the distribution is barbell-shaped rather than clustered around the middle — and bmiMD responds to only about 10–11% of its negative reviews.
The gap between the two sources is the finding
A 3.6 Trustpilot average alongside a 1.28 BBB customer review average is a wide spread. BBB reviews skew toward people escalating a dispute, but a 1.28 is low even by that standard.
Roughly one negative review in ten gets a reply
Found answers 92% of its critics and TrimRx about 72%. bmiMD answers about 10%.
You pay before you are seen
Payment is taken before the clinical consultation. If you are found ineligible you are refunded in full — but the sequence means your card is charged first.
What you get, and what simply is not there
Included
- Compounded semaglutide and compounded tirzepatide, dispensed by 503A pharmacies, availability varying by state.
- The provider visit, at no separate charge.
- Free shipping, and the same price at every dose.
- A wider ancillary menu than the others: sermorelin, NAD+, glutathione, metformin, MIC+B12 and naltrexone/bupropion/B6.
Not available
- Any branded product. No Wegovy, no Zepbound, no Ozempic, no Mounjaro. Compounded only.
- Insurance billing. None, anywhere on the site.
- Lab work. Not included.
- Human coaching. Not offered.
- A mobile app. bmiMD does not have one.
Eligibility is 18 or older with a BMI of 27 or above. bmiMD’s homepage claims availability in all 50 states, but its own March 2026 press release refers only to “states where bmiMD operates.” We treat the all-50 claim as unverified marketing until the company reconciles the two.
Cancellation and refunds
A full refund is available only if you are found ineligible. Once the pharmacy processes your order there are no refunds. Between clinician approval and pharmacy processing there is a $50 cancellation fee.
A compliance flag worth understanding before you buy
Since September 2025 the FDA has issued three waves of letters to telehealth marketers of compounded GLP-1s: roughly 80 letters plus about 40 untitled letters in September 2025, 30 announced on 3 March 2026, and 25 more in June 2026. The recipient list for the March wave was never published.
The conduct those letters cite is consistent: describing a compounded product as a “generic”, implying FDA approval, drawing equivalence between a compounded product and the branded drug, invoking facility-registration status as though it were a quality endorsement, and branding the drug with the telehealth firm’s own name to obscure where it was made.
For context on the direction of travel: the semaglutide and tirzepatide shortages were declared resolved in December 2024 and February 2025, and the compounding grace period ended in May 2025. On 30 April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List on the grounds of “no clinical need”; the comment period closed on 29 June 2026 and a final determination is pending. That proposal applies to 503B outsourcing facilities and all three programs on this site use 503A pharmacies — but nobody buying a twelve-month prepaid compounded plan today should assume the category looks the same in twelve months.
Check bmiMD’s current price →Who bmiMD is right for
Consider it if
- Price is the deciding factor. At $99/month this is the floor of the entire category, and we verified it on bmiMD’s own site rather than taking an affiliate’s word for it.
- You want one flat monthly number with no membership fee and no dose-based escalation — the same price in month twelve as in month one.
- You want a provider that publishes its potency and sterility specifications instead of saying “quality-tested” and moving on.
- You are comfortable evaluating the risk of prepaying a company with a C+ BBB rating.
- You want ancillary products like NAD+ or sermorelin from the same provider.
Avoid it if
- You want branded Wegovy or Zepbound, or any insurance involvement.
- You want to be able to read the terms you are agreeing to — the T&C page does not load.
- You expect a reply if something goes wrong; roughly one negative review in ten gets one.
- You are not comfortable paying before the clinical consultation happens.
- You want labs, coaching or an app.
Frequently asked questions
How much does bmiMD cost?
Compounded semaglutide is $129 for one month, $119/month on a 3-month term, $109/month on 6 months and $99/month on a 12-month prepaid term ($1,188 up front). Compounded tirzepatide is $179, $159, $149 and $139 on the same terms. There is no separate membership fee and the provider visit is included.
Is bmiMD legitimate?
Yes. bmiMD is the trading name of MEDCCM, Inc., a New York corporation registered in December 2022, and it has a clean regulatory record: we found no FDA warning letter, no FTC action, no state attorney general action and no lawsuit naming the company. On the other side of the ledger it holds a C+ rating from the BBB and is not accredited, with 38 complaints on file and a BBB customer review average of 1.28 out of 5.
How does bmiMD test its compounded medication?
bmiMD publishes the specifications its compounded product is tested against: potency within plus or minus 10% of label, USP <797> sterility, pH, and USP <85> bacterial endotoxin testing. Naming the specifications rather than saying "quality-tested" is unusually specific for this category. Compounded medications are still not FDA-approved, which bmiMD states plainly on its own site.
Does bmiMD take insurance?
No. There is no insurance billing anywhere on the site. FSA and HSA cards, Klarna and Afterpay are accepted.
Does bmiMD prescribe branded Ozempic or Wegovy?
No. bmiMD dispenses compounded semaglutide and compounded tirzepatide only, through 503A pharmacies. Compounded medications are not FDA-approved.
What is bmiMD's cancellation policy?
A full refund is available only if you are found ineligible. There is a $50 cancellation fee after clinician approval but before the pharmacy processes the order, and no refund once the pharmacy has processed it. These terms come from a company press release; bmiMD's own terms and conditions page returns a 404.
Is bmiMD available in all 50 states?
bmiMD's homepage says yes, but its own March 2026 press release refers only to "states where bmiMD operates." We treat the all-50 claim as unverified until the company reconciles the two statements.
Sources
- bmimd.com — homepage, semaglutide and tirzepatide product pages, pricing verified on-site 27 July 2026.
- bmimd.com — published compounded-product testing specifications (potency ±10%, USP <797> sterility, pH, USP <85> endotoxin) and compounded-medication disclosure.
- Better Business Bureau profile for MEDCCM, Inc. d/b/a bmiMD (C+ rating, non-accredited, 38 complaints, 1.28 customer review average from 25 reviews).
- Trustpilot country mirrors for bmimd.com (AU 3.7/617, CA 3.6/607, NZ 3.5/608).
- New York State corporate registration for MEDCCM, Inc.
- bmiMD press release, March 2026 (cancellation terms and state availability).
- Awin affiliate programme listing for bmiMD (company-supplied member and rating claims).
- FDA warning letters to compounded GLP-1 telehealth marketers, September 2025, 3 March 2026 and June 2026.
- FDA proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, 30 April 2026; comment period closed 29 June 2026.
Figures on this page were checked on 27 July 2026. Prices, promotions and third-party ratings change frequently — always confirm the current price on the provider’s own checkout before you pay.
Go to bmiMD →